Correspondence 0001104659-23-114484 from Hepion Pharmaceuticals, Inc. (HEPA)

Hepion Pharmaceuticals, Inc.
Date: Nov. 6, 2023 · CIK: 0001583771 · Accession: 0001104659-23-114484

View on Edgar

AI Filing Summary & Sentiment

File numbers found in text: 333-275231

Date

November 6, 2023

Author

Not clearly detected

Form

CORRESP

Company

Hepion Pharmaceuticals, Inc.

Letter

Hepion Pharmaceuticals, Inc.

399 Thornall Street, First Floor

Edison, NJ 08837

November 6, 2023

VIA EDGAR

United States Securities and Exchange Commission

100 F Street, N.E.

Washington, D.C. 20549

Attention: Tim Buchmiller

Re: Hepion Pharmaceuticals, Inc.

Form S-1 Registration Statement

Filed October 31, 2023

File No. 333-275231

Ladies and Gentlemen:

Pursuant to Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as amended, Hepion Pharmaceuticals, Inc. (the “Company”) respectfully requests that the effective date of the registration statement referred to above be accelerated so that it will become effective at 4:00 p.m., Eastern Standard Time, on Wednesday, November 8, 2023, or as soon thereafter as possible.

Please notify Jeffrey Fessler of Sheppard, Mullin, Richter & Hampton LLP, counsel to the Company, at (212) 634-3067 as soon as possible as to the time the Registration Statement has been declared effective pursuant to this acceleration request.

HEPION PHARMACEUTICALS, INC.

By: /s/ Robert Foster

Name: Robert Foster

Title: Chief Executive Officer

-1-

Show Raw Text

CORRESP
1
filename1.htm

Hepion Pharmaceuticals, Inc.

399 Thornall Street, First Floor

Edison, NJ 08837

    November 6, 2023

VIA EDGAR

United States Securities and Exchange Commission

100 F Street, N.E.

Washington, D.C. 20549

Attention: Tim Buchmiller

    Re:
    Hepion Pharmaceuticals, Inc.

    Form S-1 Registration Statement

    Filed October 31, 2023

    File No. 333-275231

Ladies and Gentlemen:

Pursuant to Rule 461
of the General Rules and Regulations under the Securities Act of 1933, as amended, Hepion Pharmaceuticals, Inc. (the “Company”)
respectfully requests that the effective date of the registration statement referred to above be accelerated so that it will become effective
at 4:00 p.m., Eastern Standard Time, on Wednesday, November 8, 2023, or as soon thereafter as possible.

Please notify Jeffrey Fessler
of Sheppard, Mullin, Richter & Hampton LLP, counsel to the Company, at (212) 634-3067 as soon as possible as to the time the Registration
Statement has been declared effective pursuant to this acceleration request.

    HEPION PHARMACEUTICALS, INC.

    By:
    /s/ Robert Foster

    Name:
    Robert Foster

    Title:
    Chief Executive Officer

    -1-

SecProbe.io